Chlamydia trachomatis vaccine development – a view on the current challenges and how to move forward

References

• Moulder JW. Interaction of chlamydiae and host cells in vitro. Microbiol Rev. 1991;55(1):143–190.
   PubMedGoogle Scholar
• McCormack WM, Benes S. Human chlamydial infections. Cutis. 1981;28(6):596–606.
   PubMed Web of Science ®Google Scholar
• Nunes A, Gomes JP. Evolution, phylogeny, and molecular epidemiology of Chlamydia. Infect Genet Evol. 2014;23:49–64.
   PubMed Web of Science ®Google Scholar
• Abraham S, Juel HB, Bang P, et al., Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect Dis. 2019. 19(10): 1091–1100.
   PubMed Web of Science ®Google Scholar
• Jordan S, Nelson D, Geisler W. Chlamydia trachomatis Infections. In: Tan M, Hegemann J, Sütterlin C, editors. Chlamydia biology: from genome to disease 2020; Caister Academic Press, 1–30. doi:10.21775/9781912530281.01.
   Google Scholar
• de Vrieze NH, de Vries HJ, de Vrieze NHN, et al. Lymphogranuloma venereum among men who have sex with men an epidemiological and clinical review. Expert Rev Anti Infect Ther. 2014;12(6):697–704.
   PubMed Web of Science ®Google Scholar
• Stoner BP, Cohen SE. Lymphogranuloma venereum 2015: clinical presentation, diagnosis, and Treatment. Clin Infect Dis. 2015;61(8):S865–873.
   PubMedGoogle Scholar
• Rowley J, Vander Hoorn S, Korenromp E, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019;97(8):548–562.
   PubMed Web of Science ®Google Scholar
• Torrone EA, Morrison CS, Chen PL, et al. Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: an individual participant data meta-analysis of 18 HIV prevention studies. Plos Med. 2018;15(2):e1002511.
   PubMed Web of Science ®Google Scholar
• Torrone EA, Morrison CS, Chen PL, et al. Correction: prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: an individual participant data meta-analysis of 18 HIV prevention studies. PLoS Med. 2018;15(6):e1002608.
   PubMedGoogle Scholar
• World Health Organization. World report on vision. WHO (Ed.^(Eds) (WHO, 2019)
   Google Scholar
• World Health Organization. WHO Alliance for the Global elimination of trachoma by 2020: progress report, 2019. WHO, 2020.
   Google Scholar
• Marks M, Bottomley C, Tome H, et al. Mass drug administration of azithromycin for trachoma reduces the prevalence of genital Chlamydia trachomatis infection in the Solomon Islands. Sex Transm Infect. 2016;92(4):261–265.
   PubMed Web of Science ®Google Scholar
• Martin DL, Bid R, Sandi F, et al. Serology for trachoma surveillance after cessation of mass drug administration. PLoS Negl Trop Dis. 2015;9(2):e0003555.
   PubMed Web of Science ®Google Scholar
• Migchelsen SJ, Sepúlveda N, Martin DL, et al. Serology reflects a decline in the prevalence of trachoma in two regions of The Gambia. Sci Rep. 2017;7(1):15040.
   PubMedGoogle Scholar
• European Centre for Diseases Prevention and Control. Lymphogranuloma venereum annual epidemiological report for 2018. (ECDC, 2020)
   Google Scholar
• Witkin SS, Minis E, Athanasiou A, et al. Chlamydia trachomatis: the persistent pathogen. Clin Vaccine Immunol. 2017;24(10). DOI:10.1128/CVI.00203-17
   PubMed Web of Science ®Google Scholar
• Hafner LM. Pathogenesis of fallopian tube damage caused by Chlamydia trachomatis infections. Contraception. 2015;92(2):108–115.
   PubMed Web of Science ®Google Scholar
• de la Maza LM, Darville TL, Pal S, et al. Chlamydia trachomatis vaccines for genital infections: where are we and how far is there to go? Expert Rev Vaccines. 2021;20(4):421–435.
   PubMed Web of Science ®Google Scholar
• Simons JL, McKenzie JS, Wright NC, et al. Chlamydia prevalence by age and correlates of infection among pregnant women. Sex Transm Dis. 2021;48(1):37–41.
   PubMed Web of Science ®Google Scholar
• Mabey DC, Hu V, Bailey RL, et al. Towards a safe and effective chlamydial vaccine: lessons from the eye. Vaccine. 2014;32(14):1572–1578.
   PubMed Web of Science ®Google Scholar
• de la Maza LM Pal S, Olsen AW. Chlamydia vaccines. In: Tan M, Hegemann JH, Sütterlin C, editors. Chlamydia biology: from genome to disease. Caister Academic Press; 2020. p. 339–384 doi:10.21775/9781912530281.15.
   Google Scholar
• Davies B, Turner KME, Frølund M, et al. Risk of reproductive complications following chlamydia testing: a population-based retrospective cohort study in Denmark. Lancet Infect Dis. 2016;16(9):1057–1064.
   PubMed Web of Science ®Google Scholar
• Reekie J, Donovan B, Guy R, et al. Risk of ectopic pregnancy and tubal infertility following gonorrhea and chlamydia infections. Clin Infect Dis. 2019;69(9):1621–1623.
   PubMed Web of Science ®Google Scholar
• Reekie J, Donovan B, Guy R, et al. Risk of pelvic inflammatory disease in relation to chlamydia and gonorrhea testing, repeat testing, and positivity: a population-based cohort study. Clin Infect Dis. 2018;66(3):437–443.
   PubMed Web of Science ®Google Scholar
• den Heijer CDJ, Hoebe C, Driessen JHM, et al. Chlamydia trachomatis and the risk of pelvic inflammatory disease, ectopic pregnancy, and female infertility: a retrospective cohort study among primary care patients. Clin Infect Dis. 2019;69(9):1517–1525.
   PubMed Web of Science ®Google Scholar
• Hoenderboom BM, van Benthem BHB, van Bergen J, et al. Relation between Chlamydia trachomatis infection and pelvic inflammatory disease, ectopic pregnancy and tubal factor infertility in a Dutch cohort of women previously tested for chlamydia in a chlamydia screening trial. Sex Transm Infect. 2019;95(4):300–306.
   PubMed Web of Science ®Google Scholar
• Hoenderboom BM, van Bergen J, Dukers-Muijrers N, et al. Pregnancies and time to pregnancy in women with and without a previous Chlamydia trachomatis infection. Sex Transm Dis. 2020;47(11):739–747.
   PubMedGoogle Scholar
• Haggerty CL, Gottlieb SL, Taylor BD, et al. Risk of sequelae after chlamydia trachomatis genital infection in women. J Infect Dis. 2010;201 Suppl 2(S2):S134–155.
   PubMedGoogle Scholar
• Price MJ, Ades AE, Soldan K, et al. The natural history of Chlamydia trachomatis infection in women: a multi-parameter evidence synthesis. Health Technol Assess. 2016;20(22):1–250.
   PubMed Web of Science ®Google Scholar
• Taylor HR, Burton MJ, Haddad D, et al. Trachoma. Lancet. 2014;384(9960):2142–2152.
   PubMed Web of Science ®Google Scholar
• Hu VH, Holland MJ, Burton MJ. Trachoma: protective and pathogenic ocular immune responses to Chlamydia trachomatis. Plos Negl Trop Dis. 2013;7(2):e2020.
   PubMed Web of Science ®Google Scholar
• West SK. Milestones in the fight to eliminate trachoma. Ophthalmic Physiol Opt. 2020;40(2):66–74.
   PubMed Web of Science ®Google Scholar
• Olsen AW, Rosenkrands I, Holland MJ, et al. A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars. NPJ Vaccines. 2021;6(1):58.
   PubMed Web of Science ®Google Scholar
• Rank RG, Yeruva L. Hidden in plain sight: chlamydial gastrointestinal infection and its relevance to persistence in human genital infection. Infect Immun. 2014;82(4):1362–1371.
   PubMed Web of Science ®Google Scholar
• Rank RG, Yeruva L. An alternative scenario to explain rectal positivity in Chlamydia-infected individuals. Clin Infect Dis. 2015;60(10):1585–1586.
   PubMed Web of Science ®Google Scholar
• Jones RB, Rabinovitch RA, Katz BP, et al. Chlamydia trachomatis in the pharynx and rectum of heterosexual patients at risk for genital infection. Ann Intern Med. 1985;102(6):757–762.
   PubMed Web of Science ®Google Scholar
• Karlsson A, Österlund A, Forssén A. Pharyngeal Chlamydia trachomatis is not uncommon any more. Scand J Infect Dis. 2011;43(5):344–348.
   PubMed Web of Science ®Google Scholar
• de Vrieze NH, van Rooijen M, Schim van der Loeff MF, et al. Anorectal and inguinal lymphogranuloma venereum among men who have sex with men in Amsterdam, The Netherlands: trends over time, symptomatology and concurrent infections. Sex Transm Infect. 2013;89(7):548–552.
   PubMed Web of Science ®Google Scholar
• Chandra NL, Broad C, Folkard K, et al., Detection of Chlamydia trachomatis in rectal specimens in women and its association with anal intercourse: a systematic review and meta-analysis. Sex Transm Infect. 2018. 94(5): 320–326.
   PubMed Web of Science ®Google Scholar
• de Vrieze NH, van Rooijen M, Speksnijder AG, et al. Urethral lymphogranuloma venereum infections in men with anorectal lymphogranuloma venereum and their partners: the missing link in the current epidemic? Sex Transm Dis. 2013;40(8):607–608.
   PubMed Web of Science ®Google Scholar
• Janssen KJH, Wolffs P, Lucchesi M, et al. Assessment of rectal Chlamydia trachomatis viable load in women by viability-PCR. Sex Transm Infect. 2020;96(2):85–88.
   PubMed Web of Science ®Google Scholar
• Statens Serum Institut. Chlamydia 2018. Statens Seum Institut; 2019.
   Google Scholar
• Zhong G, Brunham RC, de la Maza LM, et al. National institute of allergy and infectious diseases workshop report: Chlamydia vaccines: the way forward. Vaccine. 2019;37(50):7346–7354.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47(3):401–409.
   PubMed Web of Science ®Google Scholar
• Russell AN, Zheng X, O’Connell CM, et al. Analysis of factors driving incident and ascending infection and the role of serum antibody in chlamydia trachomatis genital tract infection. J Infect Dis. 2016;213(4):523–531.
   PubMed Web of Science ®Google Scholar
• Bakshi RK, Gupta K, Jordan SJ, et al. An adaptive chlamydia trachomatis-Specific IFN-gamma-Producing CD4(+) T cell response is associated with protection against chlamydia reinfection in women. Front Immunol. 2018;9:1981.
   PubMed Web of Science ®Google Scholar
• Cohen CR, Koochesfahani KM, Meier AS, et al. Immunoepidemiologic profile of Chlamydia trachomatis infection: importance of heat-shock protein 60 and interferon- gamma. J Infect Dis. 2005;192(4):591–599.
   PubMed Web of Science ®Google Scholar
• Brunham RC, Kimani J, Bwayo J, et al. The epidemiology of Chlamydia trachomatis within a sexually transmitted diseases core group. J Infect Dis. 1996;173(4):950–956.
   PubMed Web of Science ®Google Scholar
• Kimani J, Maclean IW, Bwayo JJ, et al. Risk factors for Chlamydia trachomatis pelvic inflammatory disease among sex workers in Nairobi, Kenya. J Infect Dis. 1996;173(6):1437–1444.
   PubMed Web of Science ®Google Scholar
• Molano M, Meijer CJ, Weiderpass E, et al. The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. J Infect Dis. 2005;191(6):907–916.
   PubMed Web of Science ®Google Scholar
• Batteiger BE, Xu F, Johnson RE, et al. Protective Immunity to Chlamydia trachomatis genital infection: evidence from human studies. J Infect Dis. 2010;201(S2):S178–189.
   PubMedGoogle Scholar
• Igietseme JU. The molecular mechanism of T-cell control of Chlamydia in mice: role of nitric oxide. Immunology. 1996;87(1):1–8.
   PubMed Web of Science ®Google Scholar
• Su H, Caldwell HD. CD4+ T cells play a significant role in adoptive immunity to Chlamydia trachomatis infection of the mouse genital tract. Infect Immun. 1995;63(9):3302–3308.
   PubMed Web of Science ®Google Scholar
• Loomis WP, Starnbach MN. T cell responses to Chlamydia trachomatis. Curr Opin Microbiol. 2002;5(1):87–91.
   PubMed Web of Science ®Google Scholar
• Gondek DC, Roan NR, Starnbach MN. T cell responses in the absence of IFN-gamma exacerbate uterine infection with Chlamydia trachomatis. J Immunol. 2009;183(2):1313–1319.
   PubMed Web of Science ®Google Scholar
• Gondek DC, Olive AJ, Stary G, et al. CD4+ T cells are necessary and sufficient to confer protection against Chlamydia trachomatis infection in the murine upper genital tract. J Immunol. 2012;189(5):2441–2449.
   PubMed Web of Science ®Google Scholar
• Morrison RP. Differential sensitivities of Chlamydia trachomatis strains to inhibitory effects of gamma interferon. Infect Immun. 2000;68(10):6038–6040.
   PubMed Web of Science ®Google Scholar
• Morrison SG, Morrison RP. Resolution of secondary Chlamydia trachomatis genital tract infection in immune mice with depletion of both CD4+ and CD8+ T cells. Infect Immun. 2001;69(4):2643–2649.
   PubMed Web of Science ®Google Scholar
• Morrison RP, Caldwell HD. Immunity to murine chlamydial genital infection. Infect Immun. 2002;70(6):2741–2751.
   PubMed Web of Science ®Google Scholar
• Morrison RP, Feilzer K, Tumas DB. Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection. Infect Immun. 1995;63(12):4661–4668.
   PubMed Web of Science ®Google Scholar
• Yu H, Karunakaran KP, Kelly I, et al. Immunization with live and dead Chlamydia muridarum induces different levels of protective immunity in a murine genital tract model: correlation with MHC class II peptide presentation and multifunctional TH1 cells. J Immunol. 2011;186(6):3615–3621.
   PubMed Web of Science ®Google Scholar
• Johansson M, Schon K, Ward M, et al. Genital tract infection with Chlamydia trachomatis fails to induce protective immunity in gamma interferon receptor-deficient mice despite a strong local immunoglobulin A response. Infect Immun. 1997;65(3):1032–1044.
   PubMed Web of Science ®Google Scholar
• Helble JD, Gonzalez RJ, von Andrian UH, et al. Gamma interferon is required for Chlamydia clearance but is dispensable for T cell homing to the genital tract. mBio. 2020;11(2). DOI:10.1128/mBio.00191-20
   PubMed Web of Science ®Google Scholar
• Johansson M, Schon K, Ward M, et al. Studies in knockout mice reveal that anti-chlamydial protection requires TH1 cells producing IFN-gamma: is this true for humans? Scand J Immunol. 1997;46(6):546–552.
   PubMed Web of Science ®Google Scholar
• Perry LL, Feilzer K, Caldwell HD. Immunity to Chlamydia trachomatis is mediated by T helper 1 cells through IFN-gamma-dependent and -independent pathways. J Immunol. 1997;158(7):3344–3352.
   PubMed Web of Science ®Google Scholar
• Rixon JA, Depew CE, McSorley SJ. Th1 cells are dispensable for primary clearance of Chlamydia from the female reproductive tract of mice. PLoS Pathog. 2022;18(2):e1010333.
   PubMed Web of Science ®Google Scholar
• Nguyen N, Guleed S, Olsen A, et al. Th1/Th17 T cell tissue-resident immunity increases protection, but is not required in a vaccine strategy against genital infection with Chlamydia trachomatis. Front Immunol. 2021;12:790463.
   PubMed Web of Science ®Google Scholar
• Nguyen N, Olsen AW, Lorenzen E, et al. Parenteral vaccination protects against transcervical infection with Chlamydia trachomatis and generate tissue-resident T cells post-challenge. NPJ Vaccines. 2020;5(7). DOI:10.1038/s41541-020-0157-x.
   PubMedGoogle Scholar
• Vicetti Miguel RD, Quispe Calla NE, Pavelko SD, et al. Intravaginal Chlamydia trachomatis challenge infection elicits TH1 and TH17 immune responses in mice that promote pathogen clearance and genital tract damage. Plos One. 2016;11(9):e0162445.
   PubMed Web of Science ®Google Scholar
• Andrew DW, Cochrane M, Schripsema JH, et al. The duration of Chlamydia muridarum genital tract infection and associated chronic pathological changes are reduced in IL-17 knockout mice but protection is not increased further by immunization. Plos One. 2013;8(9):e76664.
   PubMed Web of Science ®Google Scholar
• Bagri P, Anipindi VC, Nguyen PV, et al. Novel role for interleukin-17 in enhancing type 1 helper T cell immunity in the female genital tract following mucosal herpes simplex virus 2 vaccination. J Virol. 2017;91(23). DOI:10.1128/JVI.01234-17
   PubMed Web of Science ®Google Scholar
• Scurlock AM, Frazer LC, Andrews CWsJr., et al. Interleukin-17 contributes to generation of Th1 immunity and neutrophil recruitment during Chlamydia muridarum genital tract infection but is not required for macrophage influx or normal resolution of infection. Infect Immun. 2011;79(3):1349–1362.
   PubMed Web of Science ®Google Scholar
• O’Meara CP, Armitage CW, Harvie MC, et al. Immunity against a Chlamydia infection and disease may be determined by a balance of IL-17 signaling. Immunol Cell Biol. 2014;92(3):287–297.
   PubMed Web of Science ®Google Scholar
• Liu JZ, Pezeshki M, Raffatellu M. Th17 cytokines and host-pathogen interactions at the mucosa: dichotomies of help and harm. Cytokine. 2009;48(1–2):156–160.
   PubMed Web of Science ®Google Scholar
• Lu C, Zeng H, Li Z, et al. Protective immunity against mouse upper genital tract pathology correlates with high IFNgamma but low IL-17 T cell and anti-secretion protein antibody responses induced by replicating chlamydial organisms in the airway. Vaccine. 2012;30(2):475–485.
   PubMed Web of Science ®Google Scholar
• Frazer LC, Scurlock AM, Zurenski MA, et al. IL-23 induces IL-22 and IL-17 production in response to Chlamydia muridarum genital tract infection, but the absence of these cytokines does not influence disease pathogenesis. Am J Reprod Immunol. 2013;70(6):472–484.
   PubMed Web of Science ®Google Scholar
• Khader SA, Bell GK, Pearl JE, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol. 2007;8(4):369–377.
   PubMed Web of Science ®Google Scholar
• Roan NR, Starnbach MN. Immune-mediated control of Chlamydia infection. Cell Microbiol. 2008;10(1):9–19.
   PubMed Web of Science ®Google Scholar
• Olsen AW, Lorenzen EK, Follmann F, et al. A polyprotein vaccine promotes both strong Th1 and neutralizing antibody responses and confers efficient protection against genital C. trachomatis infection in mice and pigs. Thirteenth International Symposium on Human Chlamydial Infections editor, 2014.
   Google Scholar
• Olsen AW, Follmann F, Erneholm K, et al. Protection against chlamydia trachomatis infection and upper genital tract pathological changes by vaccine-promoted neutralizing antibodies directed to the VD4 of the major outer membrane protein. J Infect Dis. 2015;212(6):978–989.
   PubMed Web of Science ®Google Scholar
• Johnson RM, Brunham RC. Tissue-Resident T cells as the central paradigm of Chlamydia immunity. Infect Immun. 2016;84(4):868–873.
   PubMed Web of Science ®Google Scholar
• Sheridan BS, Lefrancois L. Intraepithelial lymphocytes: to serve and protect. Curr Gastroenterol Rep. 2010;12(6):513–521.
   PubMedGoogle Scholar
• Konjar S, Ferreira C, Blankenhaus B, et al. Intestinal barrier interactions with specialized CD8 T cells. Front Immunol. 2017;8:1281.
   PubMed Web of Science ®Google Scholar
• Freeman ML, Sheridan BS, Bonneau RH, et al. Psychological stress compromises CD8+ T cell control of latent herpes simplex virus type 1 infections. J Immunol. 2007;179(1):322–328.
   PubMed Web of Science ®Google Scholar
• Orr MT, Mathis MA, Lagunoff M, et al. CD8 T cell control of HSV reactivation from latency is abrogated by viral inhibition of MHC class I. Cell Host Microbe. 2007;2(3):172–180.
   PubMed Web of Science ®Google Scholar
• Kim SK, Angevine M, Demick K, et al. Induction of HLA class I-restricted CD8+ CTLs specific for the major outer membrane protein of Chlamydia trachomatis in human genital tract infections. J Immunol. 1999;162(11):6855–6866.
   PubMed Web of Science ®Google Scholar
• Tvinnereim A, Wizel B. CD8+ T cell protective immunity against Chlamydia pneumoniae includes an H2-M3-restricted response that is largely CD4+ T cell-independent. J Immunol. 2007;179(6):3947–3957.
   PubMed Web of Science ®Google Scholar
• Wizel B, Starcher BC, Samten B, et al. Multiple Chlamydia pneumoniae antigens prime CD8+ Tc1 responses that inhibit intracellular growth of this vacuolar pathogen. J Immunol. 2002;169(5):2524–2535.
   PubMed Web of Science ®Google Scholar
• Fling SP, Sutherland RA, Steele LN, et al. CD8+ T cells recognize an inclusion membrane-associated protein from the vacuolar pathogen Chlamydia trachomatis. Proc Natl Acad Sci U S A. 2001;98(3):1160–1165.
   PubMed Web of Science ®Google Scholar
• Gervassi AL, Grabstein KH, Probst P, et al. Human CD8+ T cells recognize the 60-kDa cysteine-rich outer membrane protein from Chlamydia trachomatis. J Immunol. 2004;173(11):6905–6913.
   PubMed Web of Science ®Google Scholar
• Starnbach MN, Loomis WP, Ovendale P, et al. An inclusion membrane protein from Chlamydia trachomatis enters the MHC class I pathway and stimulates a CD8+ T cell response. J Immunol. 2003;171(9):4742–4749.
   PubMed Web of Science ®Google Scholar
• Murthy AK, Li W, Chaganty BK, et al. Tumor necrosis factor alpha production from CD8+ T cells mediates oviduct pathological sequelae following primary genital Chlamydia muridarum infection. Infect Immun. 2011;79(7):2928–2935.
   PubMed Web of Science ®Google Scholar
• Vlcek KR, Li W, Manam S, et al. The contribution of Chlamydia-specific CD8(+) T cells to upper genital tract pathology. Immunol Cell Biol. 2016;94(2):208–212.
   PubMed Web of Science ®Google Scholar
• Igietseme JU, He Q, Joseph K, et al. Role of T lymphocytes in the pathogenesis of Chlamydia disease. J Infect Dis. 2009;200(6):926–934.
   PubMed Web of Science ®Google Scholar
• Yu H, Lin H, Xie L, et al. Chlamydia muridarum induces pathology in the female upper genital tract via distinct mechanisms. Infect Immun. 2019;87(8). DOI:10.1128/IAI.00145-19.
   Web of Science ®Google Scholar
• Magee DM, Williams DM, Smith JG, et al. Role of CD8 T cells in primary Chlamydia infection. Infect Immun. 1995;63(2):516–521.
   PubMed Web of Science ®Google Scholar
• Olivares-Zavaleta N, Whitmire WM, Kari L, et al. CD8+ T cells define an unexpected role in live-attenuated vaccine protective immunity against Chlamydia trachomatis infection in macaques. J Immunol. 2014;192(10):4648–4654.
   PubMed Web of Science ®Google Scholar
• Lijek RS, Helble JD, Olive AJ, et al. Pathology after Chlamydia trachomatis infection is driven by nonprotective immune cells that are distinct from protective populations. Proc Natl Acad Sci U S A. 2018;115(9):2216–2221.
   PubMed Web of Science ®Google Scholar
• Rank RG, Batteiger BE. Protective role of serum antibody in immunity to chlamydial genital infection. Infect Immun. 1989;57(1):299–301.
   PubMed Web of Science ®Google Scholar
• Moore T, Ananaba GA, Bolier J, et al. Fc receptor regulation of protective immunity against Chlamydia trachomatis. Immunology. 2002;105(2):213–221.
   PubMed Web of Science ®Google Scholar
• Moore T, Ekworomadu CO, Eko FO, et al. Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens. J Infect Dis. 2003;188(4):617–624.
   PubMed Web of Science ®Google Scholar
• Morrison SG, Morrison RP. The protective effect of antibody in immunity to murine chlamydial genital tract reinfection is independent of immunoglobulin A. Infect Immun. 2005;73(9):6183–6186.
   Web of Science ®Google Scholar
• Morrison SG, Su H, Caldwell HD, et al. Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4(+) T cells but not CD8(+) T cells. Infect Immun. 2000;68(12):6979–6987.
   PubMed Web of Science ®Google Scholar
• Naglak EK, Morrison SG, Morrison RP. Neutrophils are central to antibody-mediated protection against genital chlamydia. Infect Immun. 2017;85(10). DOI:10.1128/IAI.00409-17
   PubMed Web of Science ®Google Scholar
• Farris CM, Morrison SG, Morrison RP. CD4+ T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection. Infect Immun. 2010;78(10):4374–4383.
   PubMed Web of Science ®Google Scholar
• O’Meara CP, Armitage CW, Kollipara A, et al. Induction of partial immunity in both males and females is sufficient to protect females against sexual transmission of Chlamydia. Mucosal Immunol. 2016;9(4):1076–1088.
   PubMed Web of Science ®Google Scholar
• Olsen AW, Lorenzen EK, Rosenkrands I, et al. Protective effect of vaccine promoted neutralizing antibodies against the intracellular pathogen chlamydia trachomatis. Front Immunol. 2017;8:1652.
   PubMed Web of Science ®Google Scholar
• Cotter TW, Meng Q, Shen ZL, et al. Protective efficacy of major outer membrane protein-specific immunoglobulin A (IgA) and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection. Infect Immun. 1995;63(12):4704–4714.
   PubMed Web of Science ®Google Scholar
• Pal S, Theodor I, Peterson EM, et al. Monoclonal immunoglobulin A antibody to the major outer membrane protein of the Chlamydia trachomatis mouse pneumonitis biovar protects mice against a chlamydial genital challenge. Vaccine. 1997;15(5):575–582.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Huang Y, Gong S, et al. In vivo and ex vivo imaging reveals a long-lasting chlamydial infection in the mouse gastrointestinal tract following genital tract inoculation. Infect Immun. 2015;83(9):3568–3577.
   PubMed Web of Science ®Google Scholar
• Perry LL, Hughes S. Chlamydial colonization of multiple mucosae following infection by any mucosal route. Infect Immun. 1999;67(7):3686–3689.
   PubMed Web of Science ®Google Scholar
• Gratrix J, Singh AE, Bergman J, et al. Evidence for increased Chlamydia case finding after the introduction of rectal screening among women attending 2 Canadian sexually transmitted infection clinics. Clin Infect Dis. 2015;60(3):398–404.
   PubMed Web of Science ®Google Scholar
• Rank RG, Sanders MM. Pathogenesis of endometritis and salpingitis in a Guinea pig model of chlamydial genital infection. Am J Pathol. 1992;140(4):927–936.
   PubMed Web of Science ®Google Scholar
• Morrison SG, Morrison RP. In situ analysis of the evolution of the primary immune response in murine Chlamydia trachomatis genital tract infection. Infect Immun. 2000;68(5):2870–2879.
   PubMed Web of Science ®Google Scholar
• Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105(43):16731–16736.
   PubMed Web of Science ®Google Scholar
• Round JL, Lee SM, Li J, et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science. 2011;332(6032):974–977.
   PubMed Web of Science ®Google Scholar
• Bax CJ, Quint KD, Peters RP, et al. Analyses of multiple-site and concurrent Chlamydia trachomatis serovar infections, and serovar tissue tropism for urogenital versus rectal specimens in male and female patients. Sex Transm Infect. 2011;87(6):503–507.
   PubMed Web of Science ®Google Scholar
• He C, Xu Y, Huo Z, et al. Regulation of Chlamydia spreading from the small intestine to the large intestine via an immunological barrier. Immunol Cell Biol. 2021;99(6):611–621.
   PubMed Web of Science ®Google Scholar
• Shin H, Iwasaki A. Tissue-resident memory T cells. Immunol Rev. 2013;255(1):165–181.
   PubMed Web of Science ®Google Scholar
• Schenkel JM, Masopust D. Tissue-resident memory T cells. Immunity. 2014;41(6):886–897.
   PubMed Web of Science ®Google Scholar
• Szabo PA, Miron M, Farber DL. Location, location, location: tissue resident memory T cells in mice and humans. Sci Immunol. 2019;4(34). DOI:10.1126/sciimmunol.aas9673
   PubMed Web of Science ®Google Scholar
• Stary G, Olive A, Radovic-Moreno AF, et al. VACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells. Science. 2015;348(6241):aaa8205.
   PubMed Web of Science ®Google Scholar
• Shillova N, Howe SE, Hyseni B, et al. Chlamydia-Specific IgA secretion in the female reproductive tract induced via per-oral immunization confers protection against primary chlamydia challenge. Infect Immun. 2020;89(1). DOI:10.1128/IAI.00413-20
   PubMed Web of Science ®Google Scholar
• Shin HN, Iwasaki A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature. 2012;491(7424):463–+.
   PubMed Web of Science ®Google Scholar
• Iijima N, Iwasaki A. T cell memory. A local macrophage chemokine network sustains protective tissue-resident memory CD4 T cells. Science. 2014;346(6205):93–98.
   PubMed Web of Science ®Google Scholar
• Pal S, Cruz-Fisher MI, Cheng C, et al. Vaccination with the recombinant major outer membrane protein elicits long-term protection in mice against vaginal shedding and infertility following a Chlamydia muridarum genital challenge. NPJ Vaccines. 2020;5(1):90.
   PubMed Web of Science ®Google Scholar
• Wern JE, Sorensen MR, Olsen AW, et al. Simultaneous subcutaneous and intranasal administration of a CAF01-Adjuvanted chlamydia vaccine elicits elevated IgA and protective Th1/Th17 responses in the genital tract. Front Immunol. 2017;8:569.
   PubMed Web of Science ®Google Scholar
• Lorenzen E, Follmann F, Boje S, et al. Intramuscular priming and intranasal boosting induce strong genital immunity through secretory IgA in minipigs infected with chlamydia trachomatis. Front Immunol. 2015;6:628.
   PubMed Web of Science ®Google Scholar
• Carmichael JR, Pal S, Tifrea D, et al. Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine. Vaccine. 2011;29(32):5276–5283.
   PubMed Web of Science ®Google Scholar
• Lewis DJ, Huo Z, Barnett S, et al. Transient facial nerve paralysis (Bell’s palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. Plos One. 2009;4(9):e6999.
   PubMed Web of Science ®Google Scholar
• Paes W, Brown N, Brzozowski AM, et al. Recombinant polymorphic membrane protein D in combination with a novel, second-generation lipid adjuvant protects against intra-vaginal Chlamydia trachomatis infection in mice. Vaccine. 2016;34(35):4123–4131.
   PubMed Web of Science ®Google Scholar
• Abraham S, Juel HB, Bang P, et al. Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect Dis. 2019;19(10):1091–1100.
   PubMed Web of Science ®Google Scholar
• Igietseme J, Eko F, He Q, et al. Delivery of Chlamydia vaccines. Expert Opin Drug Deliv. 2005;2(3):549–562.
   PubMedGoogle Scholar
• Kelly KA, Rank RG. Identification of homing receptors that mediate the recruitment of CD4 T cells to the genital tract following intravaginal infection with Chlamydia trachomatis. Infect Immun. 1997;65(12):5198–5208.
   PubMed Web of Science ®Google Scholar
• Rockey DD, Wang J, Lei L, et al. Chlamydia vaccine candidates and tools for chlamydial antigen discovery. Expert Rev Vaccines. 2009;8(10):1365–1377.
   PubMed Web of Science ®Google Scholar
• Hafner LM, McNeilly C. Vaccines for Chlamydia infections of the female genital tract. Future Microbiol. 2008;3(1):67–77.
   PubMed Web of Science ®Google Scholar
• Pal S, Davis HL, Peterson EM, et al. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge. Infect Immun. 2002;70(9):4812–4817.
   PubMed Web of Science ®Google Scholar
• He Q, Martinez-Sobrido L, Eko FO, et al. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines. Immunology. 2007;122(1):28–37.
   PubMed Web of Science ®Google Scholar
• Li W, Murthy AK, Guentzel MN, et al. Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection. J Immunol. 2008;180(5):3375–3382.
   PubMed Web of Science ®Google Scholar
• Pal S, Theodor I, Peterson EM, et al. Immunization with an acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge. Infect Immun. 1997;65(8):3361–3369.
   PubMed Web of Science ®Google Scholar
• Pal S, Fielder TJ, Peterson EM, et al. Protection against infertility in a BALB/c mouse salpingitis model by intranasal immunization with the mouse pneumonitis biovar of Chlamydia trachomatis. Infect Immun. 1994;62(8):3354–3362
   PubMed Web of Science ®Google Scholar
• Tifrea DF, Pal S, Popot JL, et al. Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum. J Immunol. 2014;192(11):5201–5213.
   PubMed Web of Science ®Google Scholar
• Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N Engl J Med. 2004;350(9):896–903.
   PubMed Web of Science ®Google Scholar
• Jiang J, Liu G, Kickhoefer VA, et al. A protective vaccine against chlamydia genital infection using vault nanoparticles without an added adjuvant. Vaccines (Basel). 2017;5(1).
   PubMed Web of Science ®Google Scholar
• Darville T, Andrews CWsJr., Laffoon KK, et al. Mouse strain-dependent variation in the course and outcome of chlamydial genital tract infection is associated with differences in host response. Infect Immun. 1997;65(8):3065–3073.
   PubMed Web of Science ®Google Scholar
• Howe SE, Shillova N, Konjufca V. Dissemination of Chlamydia from the reproductive tract to the gastro-intestinal tract occurs in stages and relies on Chlamydia transport by host cells. PLoS Pathog. 2019;15(12):e1008207.
   PubMed Web of Science ®Google Scholar
• Cotter TW, Ramsey KH, Miranpuri GS, et al. Dissemination of Chlamydia trachomatis chronic genital tract infection in gamma interferon gene knockout mice. Infect Immun. 1997;65(6):2145–2152.
   PubMed Web of Science ®Google Scholar
• Yeruva L, Spencer N, Bowlin AK, et al. Chlamydial infection of the gastrointestinal tract: a reservoir for persistent infection. Pathog Dis. 2013;68(3):88–95
   PubMed Web of Science ®Google Scholar
• Wang L, Zhu C, Zhang T, et al. Nonpathogenic colonization with chlamydia in the gastrointestinal tract as oral vaccination for inducing transmucosal protection. Infect Immun. 2018;86(2). 10.1128/IAI.00630-17.
   Web of Science ®Google Scholar
• Zhu C, Lin H, Tang L, et al. Oral Chlamydia vaccination induces transmucosal protection in the airway. Vaccine. 2018;36(16):2061–2068.
   PubMed Web of Science ®Google Scholar
• Christensen D, Bollehuus Hansen L, Leboux R, et al. A liposome-based adjuvant containing two delivery systems with the ability to induce mucosal immunoglobulin a following a parenteral immunization. ACS Nano. 2019;13(2):1116–1126.
   PubMed Web of Science ®Google Scholar
• Darville T, Hiltke TJ. Pathogenesis of genital tract disease due to chlamydia trachomatis. J Infect Dis. 2010;201(S2):S114–125.
   PubMedGoogle Scholar
• Sowa S, Sowa J, Collier LH, et al. Trachoma vaccine field trials in The Gambia. J Hyg (Lond). 1969;67(4):699–717.
   PubMedGoogle Scholar
• Wiesenfeld HC. Screening for chlamydia trachomatis infections in women. N Engl J Med. 2017;376(8):765–773.
   PubMed Web of Science ®Google Scholar
• Hitchings MD, Grais RF, Lipsitch M. Using simulation to aid trial design: ring-vaccination trials. Plos Negl Trop Dis. 2017;11(3):e0005470.
   PubMed Web of Science ®Google Scholar
• Ebola ça Suffit Ring Vaccination Trial Consortium. The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola. BMJ. 2015;351:h3740.
   PubMedGoogle Scholar
• McIntosh EDG. Development of vaccines against the sexually transmitted infections gonorrhoea, syphilis, Chlamydia, herpes simplex virus, human immunodeficiency virus and Zika virus. Ther Adv Vaccines Immunother. 2020;8:2515135520923887.
   Google Scholar
• Quinn TC, Gaydos C, Shepherd M, et al. Epidemiologic and microbiologic correlates of Chlamydia trachomatis infection in sexual partnerships. JAMA. 1996;276(21):1737–1742.
   PubMed Web of Science ®Google Scholar
• Molina JM, Charreau I, Chidiac C, et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis. 2018;18(3):308–317.
   PubMed Web of Science ®Google Scholar